NEW YORK (GenomeWeb News) — Accelrys has purchased Scynexis' web-based Hit Explorer Operating System, or HEOS, a product which Accelrys began marketing last October under a reseller agreement as part of its cheminformatics offering.
Combined with its cheminformatics offerings, the HEOS platform enables collaborative drug discovery by providing access to chemical registration, biological assay results, computational and visual analytics, safety assessment and pharmacokinetics data, and other project information in a cloud-based infrastructure, Accelrys said this week.
Accelrys President and CEO Max Carnecchia said in a statement that the firm looks forward to "broadening the applicability and reach of HEOS as a secure, easy-to-use, Cloud-based information management workspace" as many of the company's customers engage in "multi-site [and] multi-collaborator projects."
Accelrys said that its purchase of the HEOS software-as-a service-based system includes software and supporting personnel, but it did not provide additional information. Financial details of the acquisition also were not disclosed.